Mode
Text Size
Log in / Sign up

Complete revascularization shows high probability of benefit for NSTEMI patients with multivessel diseaseComplete revascularization shows high probability of benefit for NSTEMI patients with multivessel disease

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Consider complete revascularization for NSTEMI with multivessel disease given high probability of benefit.

This study utilized a Bayesian re-analysis approach to examine outcomes in patients presenting with non-ST-elevation myocardial infarction and multivessel disease. The investigators compared complete revascularization against a strategy of treating only the culprit lesion. The primary analysis focused on a composite outcome including all-cause death, nonfatal myocardial infarction, repeat revascularization, and stroke.

The authors reported a high probability of benefit for the complete revascularization strategy regarding the primary composite endpoint. Qualitative analysis of secondary outcomes suggested a reduction in the need for repeat procedures and a trend toward fewer nonfatal heart attacks. The probability of achieving a clinically meaningful difference was high for the primary outcome.

The authors noted that this work represents a post hoc re-analysis rather than a new prospective trial. They observed that results were consistent across multiple statistical priors, which supports the robustness of the findings. However, the study design inherently limits the ability to establish definitive causality. Clinicians should interpret these results as supportive evidence rather than definitive proof of superiority.

This study looked at patients presenting with non-ST-elevation myocardial infarction and multivessel disease. The researchers performed a Bayesian re-analysis of a previous trial to evaluate treatment options. They compared complete revascularization against culprit-only revascularization. The analysis included 478 patients in the population. Results showed a high probability of benefit for the composite endpoint of death, heart attack, repeat procedures, and stroke. The probability of any benefit was 99.8%. There was also a high probability of clinically relevant benefit for repeat revascularization. A benefit for nonfatal heart attack was also likely. Safety concerns were not reported in this analysis. The main reason to be careful is that this is a post hoc re-analysis. Results were consistent across all priors used. Readers should take away that complete revascularization provides a high probability of clinically meaningful benefit in these specific patients. This finding comes from a re-analysis rather than a new trial. The evidence supports a link between the procedure and improved outcomes in this group.

What this means for you:
Complete revascularization shows high probability of benefit for NSTEMI patients with multivessel disease in this re-analysis.

Study Details

Study typeRct
Sample sizen = 240
EvidenceLevel 2
PublishedJun 2026
View Original Abstract ↓
BACKGROUND: The completeness of revascularization in patients presenting with non-ST-elevation myocardial infarction (NSTEMI) and multivessel disease (MVD) remains understudied. The SLIM trial previously demonstrated a significant reduction in a composite endpoint of all-cause death, nonfatal myocardial infarction (MI), repeat revascularization, and stroke with complete revascularization under a frequentist framework. This post hoc Bayesian re-analysis offers a probabilistic interpretation beyond conventional significance testing. METHODS: The primary composite endpoint was analyzed as in the original trial, while secondary endpoints of the composite were evaluated individually. Analyses under multiple priors assessed robustness. The minimal clinically important difference (MCID) was defined as 5% absolute risk difference (ARD) for the composite endpoint and 1% for individual endpoints. The primary model used a weakly informative prior on the log relative risk (RR) scale within a normal-normal Bayesian framework. RESULTS: Total 478 patients were randomized (complete: n = 240; culprit-only: n = 238). The posterior median RR for the composite endpoint was 0.41 (95% credible interval [CrI] 0.22-0.76), corresponding to an ARD of -7.9% (95% CrI -10.4% to -3.2%). The probability of any benefit was 99.8%, and the probability of meeting the MCID was 91.2%. For repeat revascularization, the ARD was -8.3% (95% CrI -10.0% to -4.5%), with a > 99.9% probability of clinically relevant benefit. For nonfatal MI, the ARD was -2.8% (95% CrI -4.2% to 0.9%), with a 94.8% probability of benefit. Results were consistent across all priors. CONCLUSION: Complete revascularization provides a high probability of clinically meaningful benefit in NSTEMI patients with MVD, primarily through reductions in nonfatal MI and repeat revascularization.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.